PBM_OUT_1 [2025-04-28 06:25:16 -0400] 5977 Bytes | 1553 tokens | Cum: 1553 tkns (19.41% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Psyence Biomedical (PBM) which is at $0.5349 up from $0.4620. So, I pulled together a bunch of data for you to look over real fast. It's still early, 6:25 AM on Mon Apr 28, 2025. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Psyence Biomedical (PBM)
IPO: 2024-01-26 (1 Year Ago)
Market Cap: $1,831,676
Shares Outstanding: 4,530,000
Exchange: XNAS
Description: Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Here’s a list of headlines for Psyence Biomedical:

Apr-17-25 07:17PM - Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Apr-17-25 07:17PM 09:39AM - Psyence Group Announces Share Consolidation
Apr-15-25 08:30AM - Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement
Apr-08-25 08:00AM - Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia
Mar-31-25 08:00AM - Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
Mar-25-25 10:47AM - Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein
Mar-18-25 08:30AM - Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein
Mar-10-25 11:18AM - Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
Feb-26-25 08:00AM - Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
Dec-27-24 04:05PM - Psyence Biomed Announces Closing of $2.0 Million Private Placement
Dec-24-24 05:57PM - Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position
Dec-23-24 08:00AM - Psyence Biomed Announces $2.0 Million Private Placement
Dec-23-24 08:00AM 07:30AM - Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
Dec-17-24 08:37AM - Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial
Dec-17-24 08:37AM 02:30AM - Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial
Dec-11-24 07:35AM - Psyence Biomedical executes binding agreements with Optimi Health
Dec-10-24 07:30AM - Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
Dec-06-24 11:06AM - Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
Dec-03-24 07:30AM - Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress
Nov-24-24 08:44PM - Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Nov-20-24 07:30AM - Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
Nov-19-24 04:05PM - Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-12-20T10:37:57Z - US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone'
B2 - 2024-10-31T11:30:00Z - Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs
B3 - 2024-09-19T11:30:00Z - Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
B4 - 2024-09-06T11:30:00Z - Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
B5 - 2024-08-30T11:00:00Z - Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
B6 - 2024-05-17T11:00:00Z - Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Psyence Biomedical (PBM).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

PBM_OUT_3 [2025-04-28 06:25:18 -0400] 862 Bytes | 217 tokens | Cum: 1772 tkns (22.15% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/24/10/g41649387/psyence-biomedical-announces-closing-of-previously-announced-acquisition-of-psyence-groups-stake-iPsyence Biomedical has acquired an 11.13% stake in PsyLabs, a company focused on the cultivation and production of psychedelic active pharmaceutical ingredients. The acquisition is expected to benefit Psyence Biomedical's pipeline of psychedelic-based therapeutics.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PBM_OUT_5 [2025-04-28 06:25:18 -0400] 984 Bytes | 271 tokens | Cum: 2045 tkns (25.56% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-25T17:06:15Z - 12 Health Care Stocks Moving In Friday's Intraday Session - Coeptis Therapeutics (NASDAQ:COEP), Cycl...
A2 - 2025-04-17T23:28:03Z - Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency By Investing.com...
A3 - 2025-04-17T23:26:00Z - Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency...
A4 - 2025-04-17T23:31:02Z - Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency...
A5 - 2025-04-17T23:26:03Z - Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PBM_OUT_7 [2025-04-28 06:25:19 -0400] 1181 Bytes | 351 tokens | Cum: 2398 tkns (29.98% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Friday's Intraday Session - Coeptis Therapeutics (NASDAQ:COEP), Cyclacel Pharmaceuticals (NASDAQ:CYCC)**Date: 2025-04-25Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/45015979/12-health-care-stocks-moving-in-fridays-intraday-sessionGainers Jaguar Health JAGX stock increased by 61.0% to $12.98 during Friday's regular session. The company's market cap stands at $8.7 million. China SXT Pharmaceuticals SXTC shares increased by 42.96% to $2.26. The company's market cap stands at $31.0 million. Cyclacel Pharmaceuticals CYCC shares rose 23.66% to $0.28. The market value of their outstanding shares is at $3.9 million. Vicarious Surgical RBOT stock rose 15.48% to $7.68. The market value of their outstanding shares is at $45.5 million. ENDRA Life Sciences NDRA stock rose 15.06% to $3.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PBM_OUT_9 [2025-04-28 06:25:20 -0400] 1181 Bytes | 359 tokens | Cum: 2759 tkns (34.49% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): 97. The company's market cap stands at $2.1 million. Psyence Biomedical PBM stock rose 14.45% to $0.53. The market value of their outstanding shares is at $2.3 million. Losers Coeptis Therapeutics COEP shares declined by 36.9% to $7.86 during Friday's regular session. The company's market cap stands at $25.4 million. Summit Therapeutics SMMT stock fell 36.76% to $23.21. The company's market cap stands at $17.1 billion. Intensity Therapeutics INTS shares fell 33.66% to $0.6. The company's market cap stands at $9.0 million. VYNE Therapeutics VYNE stock declined by 23.75% to $1.43. The company's market cap stands at $21.1 million. Sutro Biopharma STRO stock decreased by 21.4% to $1.02. The company's market cap stands at $85.6 million. Instil Bio TIL stock declined by 21.1% to $15.47. The market value of their outstanding shares is at $101.4 million. See Also: www.benzinga.com/money/best-hea

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PBM_OUT_11 [2025-04-28 06:25:20 -0400] 1084 Bytes | 353 tokens | Cum: 3114 tkns (38.92% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): lthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

COEPCoeptis Therapeutics Holdings Inc$7.95-36.3%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum98.58Price TrendShortMediumLongOverviewCYCCCyclacel Pharmaceuticals Inc$0.23000.44%INTSIntensity Therapeutics Inc$0.5715-36.5%JAGXJaguar Health Inc$11.6444.4%NDRAENDRA Life Sciences Inc$3.9414.2%PBMPsyence Biomedical Ltd$0.516912.4%RBOTVicarious Surgical Inc$7.6815.5%SMMTSummit Therapeutics Inc$23.21-36.8%STROSutro Biopharma Inc$1.02-21.1%SXTCChina SXT Pharmaceuticals Inc$2.2039.2%TILInstil Bio Inc$15.06-23.2%VYNEVYNE Therapeutics Inc$1.46-22.3%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PBM_OUT_13 [2025-04-28 06:25:22 -0400] 238 Bytes | 59 tokens | Cum: 3175 tkns (39.69% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PBM_OUT_15 [2025-04-28 06:25:22 -0400] 251 Bytes | 78 tokens | Cum: 3256 tkns (40.70% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

PBM_OUT_17 [2025-04-28 06:25:28 -0400] 4889 Bytes | 1175 tokens | Cum: 4434 tkns (55.43% of 8k)
==========================================================================

This is our set of metrics for Psyence Biomedical.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-------------------+
| Volume: 188,044 | Perf Month: -10.89% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+-------------------+
| Avg Volume: 271.49K | Perf Quarter: -69.79% | Short Float: 33.43% | ROE: - |
+---------------------+-----------------------+------------------------+-------------------+
| Rel Volume: 0.66 | Index: - | Short Ratio: 0.70 | ROI: - |
+---------------------+-----------------------+------------------------+-------------------+
| RSI (14): 46.77 | Market Cap: 2.49M | Short Interest: 0.19M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+-------------------+
| ATR (14): 0.08 | Shs Outstand: 0.61M | Beta: -0.13 | EPS Surprise: - |
+---------------------+-----------------------+------------------------+-------------------+
| SMA20: 11.18% | Shs Float: 0.57M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+-------------------+
| SMA50: -29.72% | Inst Own: 93.39% | Sales past 5Y: 0.00% | Earnings: - |
+---------------------+-----------------------+------------------------+-------------------+
| SMA200: -94.49% | Insider Own: 20.74% | Employees: 10 | |
+---------------------+-----------------------+------------------------+-------------------+
| Perf Week: 25.50% | Insider Trans: 0.00% | Debt/Eq: - | |
+---------------------+-----------------------+------------------------+-------------------+

The next section covers any insider trading by Psyence Biomedical officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.5498
Average Volume: 108598.0
30-Day High: 0.6
30-Day Low: 0.4046
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Psyence Biomedical (PBM).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Psyence Biomedical.

2) MARKET_SCORE[]
This conversation was initiated because PBM is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for PBM.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, PBM could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect PBM to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Psyence Biomedical.

11) ETHICAL_RATING[]
Rate Psyence Biomedical’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Psyence Biomedical.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

PBM_IN_19 [2025-04-28 06:25:29 -0400] 126 Bytes | 29 tokens | Cum: 4708 tkns (58.85% of 8k)
==========================================================================

====================================
[2025-04-28 06:25:29] # Analysis Completed
Elapsed Time: 13.28 seconds